Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration.
about
Defining response to anti-VEGF therapies in neovascular AMDTreatment of Neovascular Age-Related Macular Degeneration with Anti-VEGF Agents: Predictive Factors of Long-Term Visual OutcomesNeovascular Age-Related Macular Degeneration in the Very Old (≥90 Years): Epidemiology, Adherence to Treatment, and Comparison of Efficacy.Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseasesDiagnostic accuracy of the Amsler grid and the preferential hyperacuity perimetry in the screening of patients with age-related macular degeneration: systematic review and meta-analysisFunduscopic results after 4-year follow-up treatment with ranibizumab for age-related macular degeneration in a region of SpainEffects of Vitreomacular Traction on Ranibizumab Treatment Response in Eyes with Neovascular Age-related Macular DegenerationThe retinal disease screening study: prospective comparison of nonmydriatic fundus photography and optical coherence tomography for detection of retinal irregularitiesInclusion of genotype with fundus phenotype improves accuracy of predicting choroidal neovascularization and geographic atrophyHandheld shape discrimination hyperacuity test on a mobile device for remote monitoring of visual function in maculopathy.Visual outcomes in relation to time to treatment in neovascular age-related macular degeneration.Appropriateness of quality standards for meaningful intercentre comparisons of aflibercept service provision for neovascular age-related macular degeneration.Improved Adherence to Vision Self-monitoring with the Vision and Memory Stimulating (VMS) Journal for Non-neovascular Age-related Macular Degeneration during a Randomized Controlled Trial.Disparities in access to anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration.[Delayed treatment initiation of more than 2 weeks. Relevance for possible gain of visual acuity after anti-VEGF therapy under real life conditions (interim analysis of the prospective OCEAN study)].Investigation of time to first presentation and extrahospital factors in the treatment of neovascular age-related macular degeneration: a retrospective cross-sectional study.Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany.[Reasons for delayed and discontinued therapy in age-related macular degeneration].The Finnish national guideline for diagnosis, treatment and follow-up of patients with wet age-related macular degeneration.Accuracy of a Self-monitoring Test for Identification and Monitoring of Age-related Macular Degeneration: A Diagnostic Case-control Study.A Tablet-Based Retinal Function Test in Neovascular Age-Related Macular Degeneration Eyes and At-Risk Fellow Eye.Three-month outcome of ziv-aflibercept for exudative age-related macular degeneration.[Anti-VEGF therapy for neovascular age-related macular degeneration -therapeutic strategies: statement of the German Ophthalmological Society, the German Retina Society and the Professional Association of Ophthalmologists in Germany - November 2014]Baseline Predictors of Visual Acuity Outcome in Patients with Wet Age-Related Macular Degeneration.Home Monitoring of Retinal Sensitivity on a Tablet Device in Intermediate Age-Related Macular Degeneration
P2860
Q26996510-89A9CD11-8EE6-48C8-9E16-511B11EC28CAQ33800822-1760C4CF-AF18-4098-921E-4CA8CEC24887Q33808827-E4B9331E-0285-4D80-9F18-7BE88680D07EQ33840787-B8A84CFC-DD71-4C8A-9F41-4C8292B9885FQ33891126-04B88F67-5081-4247-82DA-042AE42850ADQ34610139-E59F9397-3A7C-4EA1-B910-DDAFD8186D2DQ36342997-6D9FA6C2-C8E8-4B4D-AD21-9EE15F36A753Q36683596-D4432A8D-8665-4559-8946-D1B83FE717D6Q36961648-AA20F29F-1772-4DC4-AFD2-AF2718736352Q37095340-6548D974-0B85-4EE8-BAEA-D159B50E9104Q38527401-21DD448B-6680-4E70-9EBF-9F356ADD0AE9Q38712425-7AE9F596-9B78-4C3F-83BA-9EDDD0806BA6Q39042323-0593FF0C-C2B7-4B05-8349-3EB9524777DAQ39568835-809F6943-C0FB-4C9F-9FAB-B6769EF2F360Q41558337-136CEAAE-0CDD-470C-A82F-0BDB865B609AQ47327666-ED420904-6F0D-4F8B-8C0B-32CA260B9169Q48350996-E177E470-F9E5-4F48-817E-C4C16F6453F2Q50013368-804501AD-E57A-4CD3-A862-0740B53EE1FCQ50903375-8DA741F3-2569-47A3-AE22-3A409DE0841BQ52606074-AA891853-BC3B-450E-80A9-D3145FB8DDC8Q52689321-9269AC03-28EE-4D7A-A95C-F04F7025C9DDQ53134473-EB1CF814-B5C3-4259-BFB4-A0670B4C4B44Q55066350-499519F6-8367-4CC1-9B39-1C2B69EB2405Q55289375-7789EB71-2870-461E-82B4-E3E503095871Q58599946-5E3B0C39-2AB1-440F-AE1E-7C3E98FE4D91
P2860
Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Delay to treatment and visual ...... -related macular degeneration.
@en
type
label
Delay to treatment and visual ...... -related macular degeneration.
@en
prefLabel
Delay to treatment and visual ...... -related macular degeneration.
@en
P2093
P2860
P1476
Delay to treatment and visual ...... -related macular degeneration.
@en
P2093
Devinder S Chauhan
Gregory Hageman
Jonathan H Lim
Luba D Robman
Sanjeewa S Wickremasinghe
P2860
P304
678-86, 686.e1-2
P356
10.1016/J.AJO.2011.09.013
P407
P577
2012-01-14T00:00:00Z